FDA Clears First Human Epigenetic Reprogramming Trial in U.S. — What the Harvard-Backed Anti-Aging Therapy Could Mean for You
The Phase 1 study will monitor safety and signs of neuron rejuvenation as the company tests whether reprogramming can slow glaucoma damage.
- On Tuesday, Life Biosciences injected the drug ER-100 into the eyes of a glaucoma patient, marking the first human trial of cellular reprogramming to reverse vision deterioration.
- Harvard biologist David Sinclair founded Life Biosciences to utilize Shinya Yamanaka's discovery of genes that reset cells to a youthful, functional state.
- Clinics in Boston, New York City, Los Angeles, and Charleston are recruiting 20 patients for the Phase 1 trial, which the Food and Drug Administration approved to run through 2033.
- Billionaires including Jeff Bezos and Sam Altman have invested heavily in the field; Life Biosciences recently secured $80 million to support its research.
- Experts hope this process could cure diseases, though critics warn cellular reprogramming carries cancer risks, citing past rodent studies that resulted in 'teratomas'.
11 Articles
11 Articles
From Alt to Jung: A new therapy is being tested in the USA.Image: ShutterstockScience has once again come one step closer to the dream of eternal life: In the USA, for the first time a patient has been given a makeover.Scientists from the US company Life Biosciences want to reprogram cells in the eye of a test person in such a way that they behave again like younger cells.The patient suffers from Green Star, now it is being tested whether this m…
Staying young has been a dream of many people since time immemorial. Now, for the first time, scientists have the technology in their hands that could theoretically make it possible. In early June, the first human patient received a genetic drug that is supposed to rejuvenate their eye.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
